INDBInternet News Database 2.5 Updated 2 min ago · 297 sources Show or hide images Light or dark

Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront

Save Like Comments Compare coverage
Image from Quartz

Summary

Blackstone Life Sciences will pay $750 million to fully fund Phase 3 development of Ollin's lead drug candidate, OLN324

Description from Quartz.

Who is covering this

  1. Quartz Leans left Factuality: High US
    Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront

    Blackstone Life Sciences will pay $750 million to fully fund Phase 3 development of Ollin's lead drug candidate, OLN324

Comments

Comments need JavaScript.